Silence Therapeutics (SLN) Deferred Taxes (2024 - 2025)
Silence Therapeutics recorded quarterly Deferred Taxes of $1000.0 in Q3 2025, down 90.0% quarter-over-quarter from $10000.0 in Q2 2025, and down 97.96% year-over-year from $49000.0 in Q3 2024.
Silence Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $1000.0 for Q3 2025.
- In Q3 2025, Deferred Taxes fell 97.96% year-over-year to $1000.0; the TTM figure through Dec 2025 stood at $11000.0 (down 98.7% YoY), while the FY2025 annual figure was $11000.0, down 98.7% from the prior year.
- Deferred Taxes came in at $1000.0 for Q3 2025 at Silence Therapeutics, down from $10000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $324000.0 in Q4 2024 to a low of $1000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Dec 31, 2024 | 324,000.00 |
| Sep 30, 2024 | 49,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 244,000.00 |